Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab PK/PD and Safety in Children with Severe Eosinophilic Asthma
NCT04305405Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2019
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of benralizumab in eosinophilic asthma (EA), sponsored by AstraZeneca. Started Nov 2019; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT04305405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305405.